
## Jon Weidanz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9314967/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunology, Immunotherapy, 2004, 53, 345-357.	4.2	37
2	Biochemical Mechanism of Acetaminophen (APAP) Induced Toxicity in Melanoma Cell Lines. Journal of Pharmaceutical Sciences, 2009, 98, 1409-1425.	3.3	30
3	TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets. MAbs, 2017, 9, 603-614.	5.2	23
4	An HLA-Presented Fragment of Macrophage Migration Inhibitory Factor Is a Therapeutic Target for Invasive Breast Cancer. Journal of Immunology, 2011, 186, 6607-6616.	0.8	17
5	Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells. Expert Review of Proteomics, 2006, 3, 641-652.	3.0	15
6	Targeting cancer with bispecific antibodies. Science, 2021, 371, 996-997.	12.6	15
7	A Single-Domain TCR-like Antibody Selective for the Qa-1b/Qdm Peptide Complex Enhances Tumoricidal Activity of NK Cells via Blocking the NKG2A Immune Checkpoint. Journal of Immunology, 2022, 208, 2246-2255.	0.8	1